Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Ablation Frontiers expands US chronic atrial fibrillation trial

Ablation Frontiers : 17 January, 2008  (New Product)
Ablation Frontiers has expanded enrollment in the first ever US Investigational Device Exemption (IDE) clinical trial for interventional treatment of chronic atrial fibrillation (AF).
Approval from the US Food and Drug Administration (FDA) to proceed with the pivotal phase of the study is based on the review of an initial feasibility segment completed in August 2007.

Completion of the clinical trial, which will compare the safety and efficacy of tailored ablation therapy against traditional pharmaceutical regimens, will support a pre-market approval (PMA) application to the FDA.

Having received FDA approval to enter the pivotal phase of the trial in the fourth quarter of 2007, several patients have already been randomised into the study. Initial US treatment sites included The Lahey Clinic and Medical Center in Burlington, Massachusetts. Their first patient, with a three-year history of continuous AF, was successfully treated and returned home the next day with a normal heart rhythm. After the two-hour and ten-minute procedure, Dr. Gregory Michaud had the following enthusiastic comment, 'I am really excited about this new technology. It has two advantages that are immediately apparent. One, the catheters are simpler to use than the traditional 'point-by-point' catheters, thus reducing the time it takes to complete complex left atrial procedures. Second, the depth of the radiofrequency energy lesions is controllable, which makes damage to collateral structures, such as the oesophagus, less likely.'

The Ablation Frontiers Cardiac Ablation System, being evaluated in this clinical study, was developed under the guidance of Drs Fred Morady and Hakan Oral, at the University of Michigan. Designed to be a versatile tool kit for mapping and ablating areas of the heart where AF is most prevalent, the Cardiac Ablation System combines a novel radiofrequency (RF) energy source with a series of anatomically-designed catheters. The Ablation Frontiers system is also unique because it does not require expensive 3D navigation or robotic steering equipment that can make these types of procedures longer and more complicated.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo